Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Advertisement
Articles by Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Globally, dolutegravir is expected to be a part of treatment for approximately 15 million people living with HIV by 2021.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Anticoagulation in AFib: Risk Stratification, Therapy Selection, and Factor XI Inhibitors
2
ATTR-CM Red Flags, Treatment Evidence, and the Pharmacist's Role in Care
3
A Paradigm Shift in Lipid Management: Highlights from the NLA 2026 Scientific Sessions Opening Session
4
Vigilance in an Age of Misinformation: Rebuilding Trust Through Evidence and Connection
5